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Highlights2
3
 Escherichia coli was engineered for the production of caffeic acid.4
 Tyrosine ammonia lyase (TAL) converted 3 mM of tyrosine to 2.62 mM p-coumaric 5
acid.6
 TAL and 4-coumarate 3-hydroxylase (C3H) converted tyrosine in 1 mM caffeic 7
acid.8
 This is the first study that shows caffeic acid production using TAL and 9
CYP199A2.10
 TAL and CYP199A2 converted tyrosine in 1.56 mM caffeic acid.11
12
13
Page 3 of 37
Ac
ce
pte
d M
an
us
cri
pt
3
Heterologous production of caffeic acid from tyrosine in Escherichia coli13
14
J. L. Rodriguesa,c, R. G. Araújoa, K. L. J. Pratherb,c, L.D. Kluskensa, L.R. Rodriguesa,c*15
16
aCentre of Biological Engineering, University of Minho, 4710 - 057 Braga, Portugal17
bDepartment of Chemical Engineering, Synthetic Biology Engineering Research Center 18
(SynBERC) Massachusetts Institute of Technology, Cambridge, MA 02139, USA19
cMIT-Portugal Program, Cambridge, MA and Lisbon, Portugal20
21
J. L. Rodrigues – joana.joanalucia@deb.uminho.pt22
R. G. Araújo - rafa.gomes.ar@gmail.com23
K. L. J. Prather - kljp@mit.edu24
L.D. Kluskens – kluskens@deb.uminho.pt25
L.R. Rodrigues - lrmr@deb.uminho.pt26
27
28
*Corresponding author: Lígia R. Rodrigues 29
Address: Centre of Biological Engineering, University of Minho, 4710 - 057 30
Braga, Portugal31
Tel: (+351) 253 604 40132
Fax:  (+351) 253 604 42933
E-mail address: lrmr@deb.uminho.pt34
35
36
37
38
39
40
41
Page 4 of 37
Ac
ce
pte
d M
an
us
cri
pt
4
Abstract42
Caffeic acid is a plant secondary metabolite and its biological synthesis has attracted 43
increased attention due to its beneficial effects on human health. In this study, Escherichia 44
coli was engineered for the production of caffeic acid using tyrosine as the initial precursor 45
of the pathway. The pathway design included tyrosine ammonia lyase (TAL) from 46
Rhodotorula glutinis to convert tyrosine to p-coumaric acid and 4-coumarate 3-hydroxylase 47
(C3H) from Saccharothrix espanaensis or cytochrome P450 CYP199A2 from48
Rhodopseudomonas palustris to convert p-coumaric acid to caffeic acid. The genes were 49
codon-optimized and different combinations of plasmids were used to improve the titer of 50
caffeic acid. TAL was able to efficiently convert 3 mM of tyrosine to p-coumaric acid with 51
the highest production obtained being 2.62 mM (472 mg/L). CYP199A2 exhibited higher 52
catalytic activity towards p-coumaric acid than C3H. The highest caffeic acid production 53
obtained using TAL and CYP199A2 and TAL and C3H was 1.56 mM (280 mg/L) and 1 54
mM (180 mg/L), respectively. This is the first study that shows caffeic acid production 55
using CYP199A2 and tyrosine as the initial precursor. This study suggests the possibility of 56
further producing more complex plant secondary metabolites like flavonoids and 57
curcuminoids.58
59
Keywords: tyrosine; p-coumaric acid; caffeic acid; E. coli; biosynthesis; synthetic biology60
61
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1. Introduction64
Caffeic acid is a natural phenolic compound derived from the phenylpropanoid pathway in 65
plants. Phenylpropanoic acids, especially caffeic acid, have attracted an increased attention 66
owing to their valuable properties, including antioxidant [1], anti-inflammatory [2], 67
anticancer [3], antiviral [4], antidiabetic [5] and antidepressive [6]. Due to its 68
pharmaceutical applications there is an established market for caffeic acid production. 69
Caffeic acid is mainly obtained by extraction from plants and these extraction methods 70
include high temperatures, treatment with petroleum and solvent extraction (methanol, 71
ethyl acetate), thus being energy-intensive and environmentally unfriendly [7]. Moreover, 72
the yields obtained are low because it accumulates at low levels in plant cells. To meet the 73
phenylpropanoids market needs, it is imperative to look for new green and environmental 74
production methods to replace the traditional extraction one. One way to achieve high 75
levels of caffeic acid is the production via engineered microorganisms, such as Escherichia 76
coli [8-10].77
Natural caffeic acid production starts with the deamination of the amino acid phenylalanine 78
which is converted to cinnamic acid by phenylalanine ammonia lyase (PAL) (Fig. 1). Then, 79
cinnamic acid is converted in to p-coumaric acid by cinnamate-4-hydroxylase (C4H), and 80
caffeic acid is obtained from p-coumaric acid using 4-coumarate 3-hydroxylase (C3H). 81
Tyrosine can also be used as a precursor as some PALs also have tyrosine ammonia lyase 82
(TAL) activity [11, 12]. Since tyrosine already possesses a 4-hydroxyl group, its use is 83
advantageous as it can be directly converted to p-coumaric acid, thus decreasing the 84
number of steps to produce caffeic acid. Also, using TAL, the C4H enzyme that is essential 85
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for caffeic acid production in plants and has not yet been successfully expressed in 86
prokaryotic organisms [13] is not needed anymore. 87
In the last decade several efforts have been conducted to produce caffeic acid using 88
microorganisms. Berner et al. [14] identified sam8 and sam5 genes, encoding TAL and 89
C3H involved in caffeic acid biosynthesis in the actinomycete Saccharothrix espanaensis 90
and expressed them in Streptomyces fradiae XKS. After that, these enzymes were used to 91
produce caffeic acid in E. coli (Table 1). Other bacterial TAL (Rhodobacter capsulatus and 92
Rhodotorula glutinis) were also used for the production of p-coumaric acid and 93
hydroxyphenylacetate 3-hydroxylase (4HPA3H) from E. coli or Pseudomonas aeruginosa, 94
and cytochrome P450 CYP199A2 from Rhodopseudomonas palustris was proved to 95
convert p-coumaric acid to in caffeic acid with a high yield. 96
In this study, we describe the production of caffeic acid from tyrosine or p-coumaric acid. 97
To convert tyrosine to in p-coumaric acid we used TAL from R. glutinis. p-coumaric acid 98
was converted to in caffeic acid using C3H from S. espanaensis or CYP199A2 from R. 99
palustris. Although all these genes have previously been used in the caffeic acid 100
production, it is important to mention that, as far as we know, the caffeic acid production 101
from tyrosine using CYP199A2 in the pathway has never been attempted. Additionally, in 102
the current study, the titers of caffeic acid obtained using TAL and C3H genes were higher 103
than the ones reported in other studies using the same genes. These high yields were 104
obtained by using different combinations of plasmids and genetic arrangements. 105
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Furthermore, it is important to mention that the caffeic acid pathway can be further used to 106
produce other products of the phenylpropanoid pathway with high added-value like 107
flavonoids and curcuminoids.108
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Table 1. Caffeic acid production in Escherichia coli. Genes/organisms used in the caffeic acid biosynthetic pathway, fermentation conditions and yields.109
110
aIn some studies a tyrosine overproducing strain was used in which: tyrR (tyrosine repressor) and pheA (chorismate mutase / prephenate dehydratase) were deleted (ΔtyrR and ΔpheA) to direct the pathway only to 111
tyrosine production;  ppsA (PEP synthase) and tktA (transkelotase) were overexpressed to increase the availability of the two main precursors of aromatic amino acids biosynthesis; and tyrA (chorismate mutase /112
prephenate dehydrogenase) and aroG (3-deoxy-D-arabino-heptulosonate 7-phosphate synthase) gene sequences were modified and the feedback inhibition-resistant derivatives (tyrAfbr and aroGfbr) were overexpressed  113
to remove the transcriptional control mediated by tyrosine and phenylalanine. OpTAL means codon-optimized TAL. bTYR strain – tyrosine overproducing strain; cAn alternative route through coumaroyl-CoA and 114
caffeoyl-CoA (Fig. 1) using 4CL from P. crispus and E. coli endogenous thiosterase was tested to increase the yield but it was not successful.115
Genes – Organismsa Fermentation Conditions Titer (mg/L)b Reference
TAL - S. espanaensis
C3H - S. espanaensis
First induction in LB at 37 ºC. After 5 h cells were transferred to M9 medium 
(glucose) at 26 ºC for 36 h
(not mentioned) Choi et al. [15]
TAL - R. capsulatus
4HPA3H - E. coli
ΔtyrR; tyrAfbr-ppsA-tktA-aroGfbr
M9 medium (glucose and glycerol) at 37 ºC. After induction shake flasks 
were transferred  to 30 ºC for 48 h
50.2 (TYR strain)
12.1 (wild-type)
Lin and Yan 
[16]
TAL and opTAL - S. espanaensis 
C3H - S. espanaensis
ΔtyrR; tyrAfbr- aroGfbr
First induction in LB at 37 ºC. After 5 h cells were harvested and transferred 
to M9 medium (glucose) at 26 ºC for 36 h in shake flasks
150 (TAL, TYR strain)
40 (opTAL,  TYR strain)
42 (TAL, wild-type)
14 (opTAL, wild-type)
Kang et al. [17]
CYP199A2 (wild-type and mutant 
F185L) - R. palustris
Pdr - Pseudomonas putida
Pux - R. palustris
Potassium phosphate buffer (glucose or glycerol) at 30 ºC in shake flasks for 
24 h. 20 mM p-coumaric acid was added. 
510 (wild-type)
2800 (mutant)
Furuya et al. [8]
TAL - R. glutinis
C3H - S. espanaensis
ΔpheA ΔtyrR; tyrAfbr-aroGfbr
MOPS medium (glucose or xylose), synthetic medium (glucose or xylose) or 
LB (glucose or xylose) at 37 ºC for 72 h in test tubes;
S Synthetic medium (glucose) at 37 ºC for 7 days in bioreactor
88 (LB, glucose, test tube)
106 (bioreactor)
Zhang and 
Stephanopoulos 
[18]c
TAL - R. glutinis
4HPA3H - E. coli
ΔpheA; tyrAfbr-ppsA-tktA-aroGfbr
M9 medium (yeast extract and glycerol, or glucose and glycerol) at 37 ºC for 
72 h in shake flasks. 20 mM p-coumaric acid fed 3 h after induction and 3 
mM added afterward (wild-type case)
3820  (wild-type)
766.68 (TYR strain)
Huang et al. 
[10]
4HPA3H - P. aeruginosa
Potassium phosphate buffer (glucose or glycerol) at 30 ºC for 24 h in shake 
flasks. 20 mM of p-coumaric acid was added 4 3 times
10200
Furuya and 
Kino [9]
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2. Materials and Methods116
2.1 Bacterial strains, plasmids and chemicals117
E. coli ElectroMAXTM DH10B competent cells (Invitrogen/Life Technologies, Carlsbad, 118
CA, USA) were used for molecular cloning and vector propagation. E. coli K-12 119
MG1655(DE3) [19] was used as the host for the expression of genes under the control of 120
the T7 promoter. 121
P. putida JCM 6157 strain (ATCC 17453, Manassas, VA, USA) and R. palustris CGA009122
gDNA (ATCC BAA-98) were used to amplify the pdr and pux genes. The characteristics of 123
all the strains and plasmids used in this study are described in Table 2.124
Restriction, ligation and Q5 enzymes (NEB, Ipswich, MA, USA), QIAprep Spin Miniprep 125
Kit (Qiagen, Germantown, MD, USA), DNA Clean and Concentrator and Gel DNA 126
Recovery Kits (Zymo Research, Orange, CA, USA) and Wizard® Genomic DNA 127
Purification Kit (Promega, Madison, WI, USA) were used according to the instructions 128
provided by the manufacturers. 129
L-Tyrosine, p-coumaric acid and caffeic acid were purchased from Sigma-Aldrich 130
(Steinheim, Germany), isopropyl β-D-thiogalactopyranoside (IPTG) and Luria-Bertani 131
(LB) medium from NZYTech (Lisbon, Portugal) and anhydrotetracycline (aTc) from Acros 132
(Geel, Belgium). Glucose (Acros), Na2HPO4 (Scharlau, Sentmenat, Spain), MgSO4, 133
KH2PO4 (Riel-deHaën, Seelze, Germany), NH4Cl, NaCl, CaCO3 (Panreac, Barcelona, 134
Spain) and thiamine (Fisher Scientific, Loughborough, UK) were used to prepare the M9 135
modified salt medium. The following mineral traces and vitamins were supplemented to the 136
M9 medium: FeCl3, ZnCl2, CoCl2, CuCl2, nicotinic acid (Riedel-deHaën), NaMoO4, 137
H2BO3, pyridoxine, biotin, folic acid (Merck), riboflavin and pantothenic acid (Sigma 138
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Aldrich). Ampicillin (Applichem, Darmstadt, Germany), chloramphenicol, kanamycin 139
(NZYtech) and spectinomycin (Panreac) were used when necessary.140
141
Table 2. Bacterial strains and plasmids used in this study142
Strains Relevant Genotype Source
E. coli Electromax DH10B
F- mcrA ∆(mrr-hsdRMS-mcrBC) φ80lacZ∆M15 
∆lacX74 recA1 endA1 araD139  ∆(ara, leu)7697 
galU galK λ- rpsL nupG
Invitrogen/Life 
Technologies
E. coli K-12 MG1655(DE3) F- λ-  ilvG- rfb-50 rph-1 λ(DE3) [19]  
P. putida JCM 6157 ATCC 17453
Genomic DNA Source
R. palustris CGA009 ATCC BAA-98D-5
Plasmids Construct Source
pETDuet-1 ColE1(pBR322) ori, lacI, double T7lac, AmpR Novagen
pCDFDuet-1 CloDF13 ori, lacI, double T7lac, StrepR Novagen
pRSFDuet-1 RSF ori, lacI, double T7lac, KanR Novagen
pKVS45 p15A ori, tetR, Ptet, Amp
R [20]
pUC57_TAL
pUC57 carrying codon-optimized TAL from R. 
glutinis
GenScript
pUC57_C3H
pUC57 carrying codon-optimized C3H from S. 
espanaensis
GenScript
pUC57_CYP199A2
pUC57 carrying codon-optimized CYP199A2 from 
R. palustris
GenScript
pETDuet_TAL
pETDuet-1 carrying codon-optimized TAL from R. 
glutinis
This study
pETDuet_C3H
pETDuet-1 carrying codon-optimized C3H from S. 
espanaensis
This study
pETDuet_TAL_C3H
pETDuet_TAL carrying codon-optimized C3H 
from S. espanaensis
This study
pCDFDuet_TAL
pCDFDuet-1 carrying codon-optimized TAL from 
R. glutinis
This study
pCDFDuet_C3H
pCDFDuet-1 carrying codon-optimized C3H from 
S. espanaensis
This study
pCDFDuet_CYP
pCDFDuet-1 carrying codon-optimized 
CYP199A2 from R. palustris
This study
pCDFDuet_CYP (+7aa)
pCDFDuet-1 carrying codon-optimized 
CYP199A2 from R. palustris with the first 7 amino 
acids
This study
pCDFDuet_TAL_CYP
pCDFDuet_TAL carrying codon-optimized 
CYP199A2 from R. palustris
This study
pCDFDuet_TAL_CYP (+7aa)
pCDFDuet_TAL carrying CYP199A2 from R. 
palustris with the first 7 amino acids 
This study
pCDFDuet_TAL_CYP_op
pCDFDuet-1 carrying codon-optimized TAL from 
R. glutinis and CYP199A2 from R. palustris in an 
operon
This study
pCDFDuet_TAL_CYP(+7aa)_op
pCDFDuet-1 carrying codon-optimized TAL from 
R. glutinis and CYP199A2 from R. palustris with 
the first 7 amino acids in an operon
This study
pKVS45_TAL pKVS45 carrying codon-optimized TAL from R. This study
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glutinis
pKVS45_C3H
pKVS45 carrying codon-optimized C3H from S. 
espanaensis
This study
pRSFDuet_TAL
pRSFDuet-1 carrying codon-optimized TAL from 
R. glutinis
This study
pRSFDuet_C3H
pRSFDue-1t carrying codon-optimized C3H from 
S. espanaensis
This study
pKVS45_Pdr_Pux_op
pKVS45 carrying Pdr from P. putida and Pux from 
R. palustris in an operon
This study
pETDuet_Pdr_Pux_op
pETDuet-1 carrying Pdr from P. putida and Pux 
from R. palustris in an operon
This study
143
144
2.2 Codon-optimization and synthesis of TAL, C3H and CYP199A2 145
TAL, C3H and CYP199A2 genes were codon-optimized for E. coli, synthesized and cloned 146
in pUC57 vector by GenScript (Piscataway, NJ, USA). In addition to codon-optimization, 147
the phenylalanine residue at 185 position (F185) of CYP199A2 was replaced by leucine 148
(F185L)[8]. The DNA sequences of the codon-optimized genes are provided in Table 3. 149
Supplementary Material (Table S1).150
151
152
153
154
155
156
157
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Table 3. Gene sequences of TAL, C3H and CYP199A2 with codon optimization.158
Gene Sequence
TAL
(Rhodotorula 
glutinis)
ATGGCTCCGCGTCCGACCTCGCAATCCCAAGCTCGCACCTGCCCGACCACCCAAGTTACCCAAGTTGACATCGTTGAAAAAA
TGCTGGCGGCGCCGACCGATTCGACGCTGGAACTGGACGGCTATAGCCTGAACCTGGGTGATGTGGTTTCTGCAGCACGTAA
AGGTCGTCCGGTGCGTGTTAAAGATTCAGACGAAATTCGCTCGAAAATCGATAAAAGCGTGGAATTTCTGCGTAGCCAGCTG
AGCATGTCTGTTTACGGCGTCACCACGGGTTTCGGCGGTTCAGCCGATACCCGCACGGAAGACGCCATTTCGCTGCAGAAAG
CACTGCTGGAACATCAACTGTGCGGCGTGCTGCCGAGCTCTTTTGATAGCTTCCGCCTGGGCCGTGGTCTGGAAAACTCTCTG
CCGCTGGAAGTCGTGCGTGGTGCAATGACCATCCGTGTTAATTCCCTGACGCGCGGTCATTCAGCTGTCCGTCTGGTTGTCCT
GGAAGCGCTGACCAACTTTCTGAATCACGGTATTACGCCGATCGTGCCGCTGCGTGGTACCATTAGTGCATCCGGTGATCTG
AGCCCGCTGTCTTATATTGCAGCTGCGATCTCTGGCCACCCGGACAGTAAAGTTCATGTGGTTCACGAGGGTAAAGAAAAAA
TCCTGTACGCCCGTGAAGCTATGGCGCTGTTCAACCTGGAACCGGTCGTGCTGGGCCCGAAAGAAGGCCTGGGTCTGGTGAA
TGGTACGGCTGTTTCAGCGTCGATGGCCACCCTGGCACTGCATGATGCCCACATGCTGAGCCTGCTGAGCCAGTCTCTGACC
GCGATGACGGTCGAAGCGATGGTGGGCCATGCAGGTAGCTTTCATCCGTTCCTGCACGATGTGACCCGTCCGCACCCGACGC
AGATTGAAGTTGCAGGCAACATCCGCAAACTGCTGGAAGGTAGCCGTTTTGCGGTGCATCACGAAGAAGAAGTGAAAGTGA
AAGATGACGAAGGCATTCTGCGCCAGGATCGTTATCCGCTGCGTACCAGTCCGCAATGGCTGGGTCCGCTGGTCTCCGACCT
GATTCATGCCCACGCAGTGCTGACCATCGAAGCGGGTCAGAGTACCACGGATAACCCGCTGATTGACGTGGAAAATAAAAC
CTCTCATCACGGCGGTAACTTTCAAGCCGCAGCTGTTGCCAATACGATGGAAAAAACGCGCCTGGGCCTGGCACAGATCGGT
AAACTGAATTTCACCCAACTGACGGAAATGCTGAACGCAGGCATGAATCGTGGTCTGCCGAGCTGCCTGGCAGCAGAAGAT
CCGAGTCTGTCCTATCATTGTAAAGGCCTGGACATTGCAGCTGCGGCCTACACCTCTGAACTGGGTCATCTGGCGAACCCGG
TTACCACGCACGTCCAGCCGGCTGAAATGGCGAACCAAGCCGTGAATTCCCTGGCACTGATCTCAGCTCGTCGCACCACGGA
ATCGAATGATGTCCTGAGCCTGCTGCTGGCGACCCATCTGTATTGTGTTCTGCAGGCTATTGACCTGCGCGCGATCGAATTTG
AATTCAAAAAACAGTTTGGCCCGGCTATTGTGAGCCTGATCGATCAACACTTCGGCTCTGCCATGACCGGTAGTAACCTGCG
TGACGAACTGGTGGAAAAAGTTAATAAAACGCTGGCCAAACGCCTGGAACAGACCAACAGTTACGATCTGGTGCCGCGTTG
GCATGACGCATTTTCCTTCGCAGCTGGTACGGTTGTCGAAGTTCTGAGTTCCACCTCACTGTCGCTGGCGGCCGTCAATGCCT
GGAAAGTGGCAGCTGCGGAAAGTGCAATTTCCCTGACCCGCCAAGTGCGTGAAACGTTTTGGTCAGCAGCATCGACGTCATC
GCCGGCACTGAGCTATCTGTCTCCGCGCACCCAAATTCTGTACGCTTTTGTTCGTGAAGAACTGGGCGTCAAAGCGCGTCGC
GGCGATGTTTTCCTGGGTAAACAGGAAGTGACCATCGGTAGTAATGTTTCCAAAATCTATGAAGCTATCAAAAGCGGTCGTA
TCAATAATGTGCTGCTGAAAATGCTGGCATAA
159
160
161
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Table 3. Gene sequences of TAL, C3H and CYP199A2 with codon optimization (continuation).162
Gene Sequence
C3H
(Saccharothrix 
espanaensis)
ATGACGATTACCTCTCCGGCACCGGCTGGTCGCCTGAACAATGTCCGCCCGATGACGGGTGAAGAATACCTGGAATCCCTGC
GTGACGGCCGTGAAGTGTATATTTACGGTGAACGCGTCGATGACGTGACCACGCATCTGGCGTTCCGCAACAGCGTTCGTTC
TATCGCCCGCCTGTATGATGTCCTGCACGACCCGGCATCCGAAGGTGTTCTGCGTGTCCCGACCGATACGGGTAATGGTGGTT
TTACCCATCCGTTTTTCAAAACGGCGCGTAGCTCTGAAGACCTGGTGGCGGCCCGTGAAGCCATTGTCGGCTGGCAACGCCT
GGTGTATGGCTGGATGGGTCGTACCCCGGATTACAAAGCAGCGTTTTTCGGTACGCTGGACGCTAACGCGGAATTTTATGGC
CCGTTCGAAGCCAATGCACGTCGCTGGTATCGTGATGCACAGGAACGCGTTCTGTACTTCAACCATGCTATCGTTCACCCGCC
GGTCGATCGTGACCGTCCGGCTGATCGTACCGCAGACATTTGCGTCCATGTGGAAGAAGAAACGGATTCAGGCCTGATCGTG
TCGGGTGCCAAAGTGGTTGCAACCGGTTCTGCTATGACGAACGCGAATCTGATTGCCCACTATGGTCTGCCGGTTCGCGATA
AAAAATTTGGCCTGGTGTTCACCGTTCCGATGAACAGTCCGGGTCTGAAACTGATCTGTCGTACCTCCTATGAACTGATGGTG
GCCACGCAGGGCTCACCGTTTGATTACCCGCTGAGTTCCCGCCTGGATGAAAATGACAGCATTATGATCTTTGATCGTGTTCT
GGTCCCGTGGGAAAACGTTTTCATGTACGACGCAGGCGCGGCCAATAGCTTTGCTACCGGCTCTGGTTTCCTGGAACGCTTTA
CCTTCCATGGTTGCACGCGTCTGGCAGTGAAACTGGATTTTATTGCAGGCTGTGTTATGAAAGCTGTGGAAGTTACCGGCACC
ACGCACTTCCGCGGTGTTCAGGCGCAAGTCGGCGAAGTGCTGAACTGGCGTGATGTCTTTTGGGGTCTGTCGGACGCTATGG
CGAAAAGTCCGAATTCCTGGGTGGGCGGTAGCGTTCAGCCGAACCTGAATTATGGCCTGGCCTACCGCACCTTTATGGGCGT
GGGTTATCCGCGTATTAAAGAAATTATCCAGCAAACGCTGGGCTCTGGTCTGATCTACCTGAACTCATCGGCAGCTGATTGG
AAAAATCCGGACGTTCGCCCGTATCTGGATCGTTACCTGCGCGGCAGTCGTGGTATTCAGGCAATCGATCGTGTCAAACTGC
TGAAACTGCTGTGGGACGCAGTGGGTACCGAATTCGCAGGTCGTCATGAACTGTATGAACGCAACTACGGCGGTGATCACG
AAGGTATTCGTGTGCAGACCCTGCAAGCCTATCAGGCAAATGGTCAAGCGGCCGCACTGAAAGGCTTTGCGGAACAGTGTAT
GTCGGAATATGACCTGGATGGCTGGACCCGCCCGGACCTGATTAACCCGGGCACGTAA
CYP199A2  
(Rhodopseudom
onas palustris)
ATGACGACCGCTCCGAGCCTGATGCCGGTTACGACGCCGTCTCAACATGGTGCTGGTGTGCCGCATCTGGGTATCGACCCGT
TCGCACTGGATTATTTTGCAGACCCGTACCCGGAACAGGAAACGCTGCGTGAAGCGGGTCCGGTGGTTTATCTGGATAAATG
GAACGTTTACGGCGTCGCCCGCTATGCAGAAGTGTACGCGGTTCTGAATGATCCGCTGACCTTTTGCAGCTCTCGTGGCGTGG
GTCTGTCAGACTTCAAAAAAGAAAAACCGTGGCGCCCGCCGTCGCTGATTCTGGAAGCTGATCCGCCGGCACATACGCGTAC
CCGTGCTGTCCTGTCAAAAGTGCTGTCGCCGGCGACCATGAAACGTCTGCGCGATGGTTTTGCGGCCGCAGCTGATGCCAAA
ATCGACGAACTGCTGGCACGTGGCGGTAACATTGATGCTATCGCGGACCTGGCCGAAGCATATCCGCTGTCAGTTTTTCCGG
ATGCCATGGGTCTGAAACAGGAAGGCCGCGAAAATCTGCTGCCGTACGCTGGTCTGGTCCTGAACGCATTCGGTCCGCCGAA
TGAACTGCGTCAGAGCGCCATTGAACGCTCTGCACCGCATCAGGCGTATGTTGCGGAACAGTGCCAACGTCCGAACCTGGCA
CCGGGCGGTTTTGGTGCATGTATTCACGCATTCTCCGATACGGGCGAAATCACCCCGGAAGAAGCTCCGCTGCTGGTGCGTA
GTCTGCTGTCCGCCGGTCTGGACACCACGGTGAACGGTATCGCAGCAGCAGTTTACTGCCTGGCCCGCTTTCCGGATGAATTC
GCTCGTCTGCGTGCGGACCCGAGCCTGGCCCGTAATGCATTTGAAGAAGCAGTTCGCTTCGAATCTCCGGTCCAGACGTTTTT
CCGTACCACGACCCGCGATGTCGAACTGGCTGGTGCGACCATTGGCGAAGGTGAAAAAGTGCTGATGTTTCTGGGCAGCGCA
AATCGTGACCCGCGTCGCTGGGATGACCCGGATCGTTATGACATCACGCGCAAAACCAGTGGTCATGTTGGCTTCGGTTCCG
GCGTTCACATGTGTGTCGGTCAACTGGTGGCGCGTCTGGAAGGTGAAGTCGTGCTGGCTGCACTGGCACGTAAAGTGGCAGC
AATTGAAATCGCAGGCCCGCTGAAACGCCGTTTTAACAATACCCTGCGTGGTCTGGAAAGCCTGCCGATTCAACTGACCCCG
GCCTGA
163
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2.3 Construction of plasmids163
The genes encoding TAL and C3H were expressed in E. coli cells using the pETDuet-1, 164
pCDFDuet-1, pRSFDuet-1 and pKVS45 vectors (Table 2). The gene encoding CYP199A2 165
mutant was cloned in pCDFDuet-1 and CYP199A2 redox partners, pdr and pux genes, 166
were cloned in an operon in pKVS45 using restriction enzymes. All the primers used are 167
summarized in Table 4 3. TAL and CYP199A2 were also cloned in an operon using 168
Phusion DNA plymerase (NEB) and overlap extension polymerase chain reaction 169
(PCR)[21]. The ribosome binding site (RBS) chosen was the same used in pETDuet-1, 170
pCDFDuet-1 and pRSFDuet-1. Reverse primers of TAL gene were overlapped with 171
forward primers of the CYP199A2 gene to introduce the RBS and spacer.  Briefly, the TAL 172
and CYP199A2 genes were amplified and the overlapping strands of these intermediate 173
products hybridized in a subsequent PCR and were extended to generate the full-length 174
product amplified by flanking primers that included restriction enzyme sites for inserting 175
the operon into the plasmid.176
All construction plasmids described were verified by colony PCR or digestion and 177
sequenced by Macrogen (Amsterdam, The Netherlands) or Genewiz (Cambridge, MA, 178
USA).179
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Table 4 3. Set of primers for PCR amplification (forward and reverse primers – FW and REV).180
Primer name Primer sequencea Restriction enzyme 
TAL_pET_pCDF_pRSF_FW GGCGCGCCAAATGGCTCCGCGTCCG AscI
TAL_pET_pCDF_pRSF_REV GCGGCCGCTTATGCCAGCATTTTCAGCAG NotI
TAL_pKVS45_FW CCTAGGAAGGAGATATACCATGGGCAGCAGCCATCACCATCATCACCACAGCCAGGCTCCGCGTCCG AvrII
TAL_pKVS45_REV GGATCCTTATGCCAGCATTTTC BamHI
C3H_pET_FW AGATCTCATGACGATTACCTCTCCGGC BglII
C3H_pET_REV CTCGAGCGTGCCCGGGTTAATCAG XhoI
C3H_pKVS45_FW CCTAGGAAGGAGATATACCATGGGCAGCAGCCATCACCATCATCACCACAGCCAGACGATTACCTCTCCGGCA AvrII
C3H_pKVS45_REV GGATCCTTACGTGCCCGGGTTAATCAG BamHI
C3H_pCDF_pRSF_FW GGCGCGCCAAATGACGATTACCTCTCCGG AscI
C3H_pCDF_pRSF_REV AAGCTTTTACGTGCCCGGGTTAATC HindIII
CYP(+7aa)_pCDF_FW CATATGCATCACCATCATCACCACATGACGACCGCTCCGAGCCT NdeI
CYP_pCDF_FW CATATGCATCACCATCATCACCACATGCCGGTTACGACG NdeI
CYP_pCDF_REV CTCGAGTCAGGCCGGGGTC XhoI
TAL_op_FW GGATCCAATGGCTCCGCGTC BamHI
TAL_op_REV CGTCATGGTATATCTCCTTTTATGCCAGCATTTTCAGC -
CYP(+7aa)_op_FW ATAAAAGGAGATATACCATGACGACCGCTC -
CYP_op_REV AAGCTTTCAGGCCGGGGTC HindIII
TAL_op2_REV GGCATGGTATATCTCCTTTTATGCCAGCATTTTCAGC -
CYP_op2_FW ATAAAAGGAGATATACCATGCCGGTTACGACG -
Pdr_pKVS45_FW CCTAGGAATAATTTTGTTTAACTTTAAGAAGGAGATATAATGAACGCAAACGAC NdeI
Pdr_pKVS45_REV GAGCTCTCAGGCACTACTCAGTTCAGC SacI
Pux_pKVS45_FW GGATCCAATAATTTTGTTTAACTTTAAGAAGGAGATATAATGCCCAGTATCACGTTCATTCTT BamHI
Pux_pKVS45_REV GCATGCTCAGACCTGACGATCCGGAAT SphI
Pdr_Pux_op_pET_FW GAATTCAATGAACGCAAACGACAAC EcoRI
Pdr_Pux_op_pET_REV GATATCTCAGACCTGACGATCCG EcoRV
aStart and stop codons in bold, occasionally the start codon is placed upstream of the His6-tag sequence and no stop codon is included because of the presence of 181
a Strep-tag; restriction sites in italic; His6-tag underlined; The Ribosome Binding Site (RBS) and spacer are double underlined; In order for the sequence to remain 182
in frame one or two bases were occasionally added between the restriction site and the gene start codon.183
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2.4 Growth Conditions – p-Coumaric and Caffeic Acid Production184
E. coli cells for gene cloning, plasmid propagation, and inoculum preparation were grown 185
in LB medium at 37 ºC and 200 rpm. 186
For p-coumaric acid and/or caffeic acid production, cultures were grown at 37 ºC in 50 mL 187
LB to an optical density at 600 nm (OD600) of 0.4. IPTG and/or aTc were added at the same 188
time (unless otherwise specified) at a final concentration of 1 mM and 100 ng/mL, 189
respectively, and the culture was incubated for 5 h at 26 ºC. The cells were harvested by 190
centrifugation, resuspended in 50 mL of modified M9 minimal salt medium containing (per 191
liter): glucose (40 g), Na2HPO4 (6 g), KH2PO4 (3 g), NH4Cl (1g), NaCl (0.5 g), CaCl2 (17 192
mg), MgSO4 (58 mg), thiamine (340 mg) and CaC03 (5 g) (to control the pH), and 193
incubated at 26 ºC for 63 h. Trace elements [FeCl3 (54 mg), ZnCl2 (4 mg), CoCl2 (4 mg), 194
NaMoO4 (4 mg), CuCl2 (2 mg) and H2BO3 (1 mg)] and vitamins [riboflavin (0.84 mg), 195
folic acid (0.084 mg), nicotinic acid (12.2 mg), pyridoxine (2.8 mg), biotin (0.12 mg) and 196
pantothenic acid (10.8 mg)] were also supplemented to the M9 medium. Depending on the 197
plasmid(s) present in the strain, 100 μg/mL of ampicillin, 100 μg/mL of spectinomycin 198
and/or 50 μg/mL of kanamycin were added. IPTG and/or aTc and substrates were added at 199
time 0 of induction in M9 medium (unless otherwise stated): tyrosine, 3 mM or p-coumaric 200
acid, 2 mM. Samples of the supernatant (1.5 mL) were collected at time 0 and after 15, 24, 201
43 and 63 h. All the experiments were done in triplicate and analyzed by high-performance 202
liquid chromatography (HPLC).203
204
205
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2.5 HPLC analysis of the products206
HPLC analysis was used to quantify p-coumaric acid and caffeic acid using a HPLC system 207
from Jasco (Easton, MD, USA) (PU-2080 Plus Pump unit, LG-2080-02 Ternary Gradient 208
unit, a DG-2080-53 3-Line Degasser unit, a UV-2075 Plus Intelligent UV/VIS Detector 209
unit and AS-2057 Plus Intelligent Sampler unit) and a Grace Alltech Platinum EPS C18 210
column (3µm, 150 mm × 4.6 mm) (Grace, Columbia, MD, USA). Mobile phases A and B 211
were composed of water (0.1% trifluoroacetic acid) and acetonitrile, respectively. The 212
following gradient was used at a flow rate of 1 mL/min: 10 - 20% acetonitrile (mobile 213
phase B) for 17 min. Quantification was based on the peak areas of absorbance at 275 nm 214
(tyrosine) and 310 nm (p-coumaric acid and caffeic acid). The retention times of tyrosine, 215
p-coumaric acid and caffeic acid were 3.3, 8.0 and 11.8 min, respectively.216
2.6 Protein Analysis217
E. coli K-12 MG1655(DE3) cells harboring pETDuet-1, pETDuet_TAL, pETDuet_C3H 218
and pETDuet_TAL_C3H were grown in LB at 37 ºC to an OD600 of 0.6. IPTG was added at 219
a final concentration of 1 mM, and the culture was incubated for 24 h. Samples (10 mL 220
culture medium) were taken at times 0, 5 and 24 h. Samples were centrifuged and the cells 221
were resuspended in phosphate-buffered saline (PBS: 137 mM NaCl, 2.7 mM KCl, 10 mM 222
Na2PO4, 1.8 mM KH2PO4, pH 7.4) and further disrupted by sonication on ice for 3 min. 223
After centrifugation the protein concentration from the resulting supernatant was 224
determined using Protein Assay Dye Reagent Concentrate (BioRad, Hercules, CA, USA) 225
with bovine serum albumin (BSA) (NEB) as a standard. The expression levels of TAL and 226
C3H were evaluated through sodium dodecyl sulfate polyacrylamide gel electrophoretic 227
(SDS–PAGE). Fifteen to 20 µg of total protein were loaded onto a 4-20 % Mini-228
Page 18 of 37
Ac
ce
pte
d M
an
us
cri
pt
18
PROTEAN® TGX™ Precast Gels (BioRad). The protein marker used was Precision Plus 229
ProteinTM Unstained (BioRad). For gel staining, Bio-Safe Coomassie Stain (BioRad) was 230
used. 231
232
233
234
3. Results and Discussion235
236
3.1 Selection of the appropriate enzyme sources237
TAL was chosen from the red yeast R. glutinis, since it was reported to have the highest 238
TAL activity and a low PAL/TAL catalytic activity ratio [22-24]. TAL prefers tyrosine and 239
is therefore favored over PAL and C4H, both of which are required to begin the pathway 240
from phenylalanine (Fig. 1). This decreases the pathway number of steps and at the same 241
time eliminates the issues associated with the use of C4H. C4H is a P450-dependent 242
monooxygenase and the functional expression of plant P450 enzymes is always hard to 243
achieve in bacteria, which is mainly due to the absence of cytochrome P450 reductases 244
(CPRs)/redox partners in E. coli needed for electron transfer, and to the absence of  245
endoplasmatic reticulum which prevents the efficient translational of the membrane signal 246
modules of microsomal P450 enzymes [25]. C3H from S. espanaensis was chosen as it is 247
one of the rare cytochrome P450 enzymes that was successfully expressed in E. coli [15]248
(Table 1). CYP199A2 from R. palustris was chosen as it was effectively used in previous 249
studies to achieve one of the highest caffeic acid production from p-coumaric acid [8].250
251
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3.2 Production of p-coumaric acid from tyrosine using TAL252
In order to study p-coumaric acid production from tyrosine, codon-optimized TAL was 253
cloned in pETDuet-1, pCDFDuet-1, pRSFDuet-1 and pKVS45. Fig. 2 illustrates p-254
coumaric acid production from 3 mM of tyrosine. p-Coumaric acid was also produced from 255
endogenous tyrosine in the presence of pCDFDuet_TAL, but in a very low quantity 256
compared to conditions with tyrosine supplemented. Since the endogenous tyrosine is not 257
enough to produce p-coumaric acid in high concentrations, two strategies can be used, 258
namely supplement the medium with tyrosine or engineer E. coli to overproduce tyrosine 259
from glucose. p-Coumaric acid production using TAL was found to be highly dependent on 260
the plasmid chosen. The highest production obtained was 2.62 mM (472 mg/L) and it was 261
achieved with pRSFDuet-1, which is a high copy number plasmid. In this case, the product 262
yield was 0.87 (mol p-coumaric acid/ mol tyrosine) and the remaining tyrosine was 263
presumably used for growth and primary metabolism since no tyrosine was detected by 264
HPLC. Santos et al. [26] used a codon-optimized R. glutinis TAL with a 80% similarity to 265
the one used in this study. Although both plasmids (pETDuet-1 and pTrcHis2B) have a 266
pBR322 origin, they have different promoters, with the T7 system being stronger than the 267
trc promoter. The p-coumaric acid production obtained using pETDuet_TAL (the lowest 268
production in the current study) was higher than that reported by Santos et al. [26] after 72 269
h using pTrcHis2B (104 mg/L – 0.61 mM). They obtained a product yield of 0.23 (mol p-270
coumaric acid / mol tyrosine) in a E. coli K12 MG1655(DE3) strain. From analyzing these 271
results it can be concluded that the R. glutinis TAL used in our study and the expression 272
systems chosen are a very good option to produce p-coumaric acid.273
274
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 Fig. 2B shows the production of p-coumaric acid in the strain harboring pRSFDuet_TAL 275
over time (63 h). The results showed that the p-coumaric concentration increases along 276
time, and this trend was also observed when using other plasmid constructions (data not 277
shown). Although 63 hours of incubation is a long time, it is not unusual to prolong the 278
fermentations more than 24 h in the caffeic acid production to obtain higher titers and 279
yields, as can be observed in Table 1. Albeit the incubations can be performed at higher 280
temperatures, the production would be lower since our preliminary results showed that 281
using TAL and the other enzymes used in this study at 30 ºC and 37 ºC leads to lower titers 282
than 26 ºC (data not shown).283
284
3.3 Production of caffeic acid from p-coumaric acid using C3H 285
Caffeic acid was produced from p-coumaric acid using S. espanaensis C3H (Fig. 3). C3H, 286
although being a plant cytochrome P450 enzyme, has been successfully expressed in E. coli287
[15, 17, 18]. As previously shown in the p-coumaric acid production from tyrosine (Fig. 2), 288
the highest caffeic acid titer was also obtained with the high copy number plasmid 289
pRSFDuet-1. The titer obtained was around 0.93 mM (168 mg/L), corresponding to a 290
product yield of 0.47 (mol caffeic acid / mol p-coumaric acid).291
292
3.4 Production of caffeic acid from tyrosine using TAL and C3H 293
In a second phase of the current study, TAL and C3H were combined to produce caffeic 294
acid from 3 mM of tyrosine (Fig. 4). In a first approach, the genes were cloned together in 295
pETDuet-1. When these genes were combined, the production of caffeic acid increased 170 296
%. This increase is probably due to the fact that in this case the p-coumaric concentration in 297
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the medium is lower than when it is added directly, thus reducing the toxic effect to the 298
cells as previously described in the literature [9, 10, 27-30]. To confirm that the addition of 299
p-coumaric acid had a toxic effect to the cells, p-coumaric acid and tyrosine were added 300
separately to E. coli harbouring pETDuet-1 and pETDuet_TAL_C3H. When p-coumaric 301
acid was added, the E. coli cultures had a lower growth rate and the OD600 was 10-11% 302
lower than when tyrosine was added (data not shown). Moreover, the protein expression 303
was found to be lower. When only TAL is cloned in the pETDuet-1 plasmid the protein 304
band in the SDS gel could be clearly visualized (76.34 kDa) (data not hown) (Fig. S1). 305
However, when TAL was combined with C3H, protein production was not observed maybe 306
due to the metabolic burden imposed on the host cells by the expression of the two proteins 307
in the same plasmid. Although in small amounts, a band around 56.33 kDa corresponding 308
to C3H production could be observed. 309
Cloning TAL in pCDFDuet-1 and C3H in pETDuet-1 led to results very similar to the 310
experiments in which these enzymes were used alone to produce p-coumaric acid or caffeic 311
acid, respectively (Fig. 2A and Fig. 3). This occurs because the expression of TAL when 312
alone in the plasmid is very high (Fig. S1), leading to high production of p-coumaric acid. 313
Consequently, caffeic acid amounts are comparable to the ones obtained when p-coumaric 314
acid is added as substrate. Similar results were observed with the combination 315
pETDuet_TAL and pCDFDuet_C3H. The production of p-coumaric acid was 1.28 mM and 316
caffeic acid was 0.77 mM. Since caffeic acid is produced from p-coumaric, this suggests 317
that in total more than 2 mM of p-coumaric acid was produced. When only pETDuet_TAL 318
was used (Fig. 2A), the maximum p-coumaric acid production obtained was 0.9 mM, which 319
demonstrates that tyrosine can be converted faster if p-coumaric acid is being converted to 320
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the next product. Again we observed that caffeic acid production does not increase 321
(compared to the cases when only C3H is used and the substrate is p-coumaric acid) since 322
the p-coumaric acid concentration in the medium is still very high. The combinations 323
pKVS45_TAL/ pCDFDuet_C3H, pCDFDuet_TAL/ pKVS45_C3H and pRSFDuet_TAL/ 324
pCDFDuet_C3H showed very similar results.325
The combination pCDFDuet_TAL/pRSFDuet_C3H is very interesting as almost all the p-326
coumaric acid produced is converted to caffeic acid. In the end, only around 3 µM of p-327
coumaric acid is detected by HPLC and the concentration in time was never higher than 328
0.15 mM, meaning that almost all the p-coumaric acid being produced was being converted 329
by C3H to caffeic acid. A final caffeic acid concentration of around 1 mM (180 mg/L) was 330
obtained. This combination enabled the highest yield from tyrosine with an additional 331
benefit of having in the end a very low amount of the intermediate p-coumaric acid, 332
contrary to what was observed in the other cases. 333
Zhang and Stephanopoulos [18] used codon optimized TAL from R. glutinis and C3H from 334
S. espanaensis to produce caffeic acid. Also, the authors used a tyrosine over producing 335
strain and no tyrosine limitation was observed during the caffeic acid production. After 336
several medium optimizations, the highest titer they reported after 72 h was 106 mg/L 337
(Table 1), which is 1.7 times lower than the maximum titer obtained in the current study 338
after 63 h. Although those authors used the same plasmid to carry C3H (pRSFDuet-1), they 339
used the pTrcHis2B plasmid to carry TAL, which was previously described by Santos et al. 340
[26] and that we concluded it is not the best plasmid for this gene and to produce p-341
coumaric acid (See Production of p-coumaric acid from tyrosine using TAL section). Our 342
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study reports the highest titer of caffeic acid produced so far using the combination of TAL 343
and C3H genes.344
345
3.5 Production of caffeic acid from p-coumaric acid using CYP199A2346
Until the recent studies published using 4HPA3H [9, 10], CYP199A2 gene from R. 347
palustris was reported to produce the highest amounts of caffeic acid from p-coumaric acid 348
[8]. The results obtained in our study with CYP199A2 are summarized in Fig. 5. 349
CYP199A2 was cloned in pCDFDuet-1 and its redox partners, Pdr and Pux, were expressed 350
in another plasmid (pKVS45 or pETDuet-1) as part of an operon as described before [31, 351
32]. The first results obtained with CYP199A2 in the caffeic acid production were 352
surprisingly low as compared to the Furuya et al. [8] report. After analyzing the CYP199A2 353
DNA sequence it was verified that those authors did not use the first 21 bp of CYP199A2 354
to clone the gene. This decision was based on software results that annotated the 8th355
CYP199A2 amino acid (GTG) as a start codon before the sequence was published (T. 356
Furuya, personal communication). We also confirmed that, for example, EasyGene 1.2b 357
Server [33, 34] identified the 8th amino acid as the start codon. Based on this, we cloned 358
CYP199A2 without the first 7 amino acids. The production using this new CYP199A2 359
increased considerably the caffeic acid production compared to the original clone 360
(CYP199A2(+7aa)). Additionally, it was found that the production was more than 2.7 times 361
higher when the inducer of pKVS45_Pdr_Pux_op, aTc, was added 2.5 h after addition of 362
IPTG (to induce CYP199A2 TAL expression). The delay of induction can alleviate d the 363
metabolic burden of several plasmids [26, 35]. Since pKVS45 has CYP199A2 redox 364
partners (Pdr and Pux) and these proteins are only needed after CYP199A2 is present in a 365
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significant concentration to support its catalytic activity (NADPH- and O2- dependent 366
hydroxylation reactions), their expression can be delayed. The results obtained with 367
CYP199A2 in this case were 1.8 times better than the one obtained with C3H in pCDFDuet 368
adding p-coumaric acid (Fig. 3). Nevertheless, to improve the yield and taking into 369
consideration that the addition of a high concentration of p-coumaric acid can have a 370
detrimental effect on the caffeic acid production, as discussed before, a different feeding 371
system was tested: 1 mM of p-coumaric acid was added at time 0 of induction in M9 372
medium and 0.5 mM added at 5 h and 24 h. Caffeic acid production increased to 1.72 mM 373
(310 mg/L) using this three step feeding. This approach was successfully demonstrated 374
before for the production of caffeic acid [9, 10] and allowed us to obtain a product yield of 375
0.86 (mol caffeic acid / mol p-coumaric acid) after 63 h. Furuya et al. [8] obtained a 376
maximum yield of 0.75 (mol caffeic acid / mol p-coumaric acid) after 24 h using glycerol 377
as after testing different energy source s. When the authors used glucose, the maximum 378
yield obtained after 24 h was around 0.46 (mol caffeic acid / mol p-coumaric acid), thus 379
very similar to the one obtained in the current study after 24 h - 0.47 (mol caffeic acid / mol 380
p-coumaric acid), which suggests that glycerol is a more effective energy source to 381
regenerate NADH from NAD+ [8]. 382
Since pKVS45 time of induction with aTc seems to limit caffeic acid production, pETDuet-383
1, that is induced using IPTG similarly to pCDFDuet-1, was chosen to clone the 384
CYP199A2 redox partners and evaluate if the caffeic acid production could be increased. 385
However, the results obtained with pETDuet-1 were very similar to the ones obtained with 386
pKVS45 induced at time 0. This result is not surprising since pKVS45 alone, or combined 387
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with pCDFDuet-1, gave better overall results using TAL and C3H than the pETDuet-1 388
plasmid (Fig. 2-4).389
390
3.6 Production of caffeic acid from tyrosine using TAL and CYP199A2391
To produce caffeic acid from tyrosine, TAL and CYP199A2 were combined using different 392
approaches, namely together in the same plasmid but in different MCSs (TAL in MCS1 and 393
CYP199A2 in MCS2), or in an operon in MCS1 (Fig. 6). Both CYP199A2 sequences were 394
tested and again it was concluded that CYP199A2 starting at the 8th amino acid provides 395
better results. The low caffeic acid concentration obtained was due to the addition of aTc at 396
time zero of induction. However, even with a low concentration, it is possible to conclude 397
that the genes work better when cloned in different MCSs than when cloned in an operon. 398
Thus, this approach was chosen to proceed with other tests including pKVS45 later 399
induction with aTc; three phases of p-coumaric acid addition; and the use of another 400
plasmid to carry CYP199A2 redox partners (pETDuet-1). The results obtained were very 401
similar to the ones found with only CYP199A2 in the plasmid (Fig. 5). The expression of 402
TAL in a different plasmid (pRSFDuet-1) improved caffeic acid production. The highest 403
caffeic acid production was 1.56 mM (280 mg/L). According to these results, CYP199A2 404
with its redox partners seems to be a better option than C3H to produce caffeic acid from 405
tyrosine or p-coumaric acid.  406
Based on the above discussion, we believe that it would be advisable to, in the future, clone 407
CYP199A2 with its redox partners in different plasmids and combine them with TAL to408
confirm if caffeic acid production can be improved without a high accumulation of the 409
intermediate as its accumulation may result in suboptimal production titers. Although no 410
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kinetic parameters were determined in our study, it was possible to observe that over time 411
the conversion of tyrosine to p-coumaric acid was faster than the conversion of p-coumaric 412
acid to caffeic acid. The faster conversion of tyrosine to p-coumaric acid leads to the 413
accumulation of p-coumaric acid which represents a drawback to the caffeic acid 414
production since its toxicity leads to an even more pronounced decrease of the production. 415
The kinetic parameters of the enzymes used in this study should be determined, especially 416
regarding the C3H, since TAL and CYP199A2 kinetic parameters were characterized by 417
Xue et al. [22] and Furuya et al. [8], respectively. Furthermore, it will be important to 418
evaluate a combination of plamids that allows a fine-tuned production like the one observed 419
when TAL was cloned in pCDFDuet-1 and C3H in pRSFDuet-1, where no p-coumaric acid 420
was accumulated (Fig.4). Also, to improve the yield and to avoid the need of two separate 421
stages of cultivation for biomass/protein generation and caffeic acid production, the use of 422
potassium phosphate buffer [8, 9] or MOPS [18, 26] with glucose or glycerol should be 423
tested. The use of M9 minimal medium without the production of biomass and protein in 424
LB does not allow obtaining productions as high as the ones obtained by first using LB and 425
then transferring the cells to M9 (data not shown).426
Caffeic acid has for a long time been recognized for its therapeutic properties, which makes 427
it an attractive target for metabolic engineering and synthetic biology. We have 428
successfully designed a pathway for the production of caffeic acid via metabolic 429
engineering approaches in E. coli. We tested different genetic arrangements with two (or 430
four) genes to balance the expression of the enzymes and achieve an optimized 431
performance, and we obtained significantly different levels of caffeic acid productions. The 432
layout of genes and operons in the plasmid, as well as the use of different plasmids had an 433
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enormous impact on gene expression. In addition, codon-optimization when expressing 434
heterologous genes in E. coli was considered to improve gene expression. The repeated 435
addition of the substrate and the delay in the induction of protein expression also led to an 436
increase of the titers by decreasing the toxicity of p-coumaric acid and the metabolic burden 437
of heterologous protein expression. 438
In conclusion, the caffeic acid is a phenylpropanoic acid and this pathway can be further 439
used to produce other products of the phenylpropanoid pathway from tyrosine like 440
flavonoids, stilbenoids, isoflavonoids and curcuminoids. Until now the biosynthesis of 441
these compounds is in the range of the titers obtained in this study for p-coumaric acid and 442
caffeic acid or much lower. Therefore, the strategy of adding p-coumaric acid at 443
concentrations as high as 20 mM, concentrations used in some studies for the caffeic acid 444
production (Table 1), was considered unreasonable, especially knowing that high 445
concentrations of p-coumaric acid are toxic to the cells. For the production system to be 446
even more economically viable, the use of a tyrosine overproducing strain should be 447
considered.   448
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TAL: Tyrosine Ammonia Lyase; C3H: 4-coumarate 3-hydroxylase; PAL: Phenylalanine 456
Ammonia Lyase; C4H: cinnamate-4-hydroxylase; 4HPA3H: hydroxyphenylacetate 3-457
hydroxylase 4CL: 4-coumarate-CoA ligase; MCS: Multiple Cloning Sites; PCR: 458
Polymerase Chain Reaction; RBS: Ribosome Binding Site; HPLC: High-Performance 459
Liquid Chromatography; SDS-PAGE: Sodium Dodecyl Sulfate - Polyacrylamide Gel 460
Electrophoretic (SDS–PAGE).461
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Figure Captions:557
Fig. 1. Artificial caffeic acid biosynthetic pathway. The dashed box represents the caffeic 558
acid pathway in plants. Inside and outside the box some strategies used to produce caffeic 559
acid in E. coli are illustrated. TAL: Tyrosine ammonia lyase; C3H: 4-coumarate 3-560
hydroxylase; 4HPA3H: hydroxyphenylacetate 3-hydroxylase; 4CL: 4-coumarate-CoA 561
ligase. 562
Fig. 2. Production of p-coumaric acid using TAL from Rhodotorula glutinis using different 563
plasmids after 63 h (A) and using pRSFDuet_TAL during 63 h in M9 medium (B). (*) no 564
substrate added. TAL: Tyrosine ammonia lyase.565
Fig. 3. Production of caffeic acid using opC3H from Saccharothrix espanaensis. C3H: 4-566
coumarate 3-hydroxylase.567
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Fig. 4. Production of caffeic acid using opTAL from Rhodotorula glutinis and opC3H from 568
Saccharothrix espanaensis. TAL: Tyrosine ammonia lyase; C3H: 4-coumarate 3-569
hydroxylase.570
Fig. 5. Production of caffeic acid from p-coumaric acid using CYP199A2 from 571
Rhodotorula palustris. CYP: cytochrome P450 CYP199A2.572
Fig. 6. Production of caffeic acid using TAL from Rhodotorula glutinis and CYP199A2 573
from Rhodopseudomonas palustris. TAL: Tyrosine ammonia lyase; CYP: cytochrome P450 574
CYP199A2.575
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(2) pCDFDuet_TAL +  pETDuet_C3H 
(3) pETDuet_TAL + pCDFDuet_C3H 
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(7) pRSFDuet_TAL + pCDFDuet_C3H 
Figure 4
Page 36 of 37
Ac
ce
pte
d M
an
us
cri
pt
 
 
 
 
(1) pCDFDuet_CYP(+7aa) + pKVS45_PdrPux_op 
(2) pCDFDuet_CYP + pKVS45_PdrPux_op 
(3) pCDFDuet_CYP + pKVS45_PdrPux_op (aTc added 2,5 h later) 
(4) pCDFDuet_CYP + pKVS45_PdrPux_op (aTc added 2,5 h later; p-coumaric acid added several times) 
(5) pCDFDuet_CYP + pETDuet_PdrPux_op 
(6) pCDFDuet_CYP + pETDuet_PdrPux_op (p-coumaric acid added several times) 
Figure 5
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(1) pCDFDuet_TAL_CYP(+7aa) + pKVS45_Pdr_Pux_op 
(2) pCDFDuet_TAL_CYP + pKVS45_Pdr_Pux_op 
(3) pCDFDuetTAL_CYP(+7aa)_op + pKVS45_PdrPux_op 
(4) pCDFDuet_TAL_CYP_op + pKVS45_Pdr_Pux_op 
(5) pCDFDuet_TAL_CYP + pKVS45_Pdr_Pux_op (aTc added 2,5 h later) 
(6) pCDFDuet_TAL_CYP + pKVS45_Pdr_Pux_op (aTc added 2,5 h later and p-coumaric acid added several times) 
(7) pRSFDuet_TAL + pCDFDuet_CYP + pKVS45_Pdr_Pux_op (aTc added 2,5 h later) 
(8) pCDFDuet_TAL_CYP + pETduet_Pdr_Pux_op 
(9) pRSFDuet_TAL + pCDFDuet_CYP + pETDuet_Pdr_Pux_op 
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